Press Releases
-
Jan 6, 2020
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in the 38th Annual J.P. Morgan Healthcare Conference...
-
Jan 2, 2020Single Dose Resulted in Sustained Mean Reduction of 96% in Bleed Rates at 6e13 vg/kg Dose in Third Year
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the New England Journal of Medicine (NEJM) published an independently peer-reviewed article on up to three years of data from an...
-
Dec 23, 20191st Marketing Application Submission in U.S. for Gene Therapy Directed at Any Type of Hemophilia
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its investigational...
-
Dec 23, 2019Potential 1st Gene Therapy in Europe Directed at Any Type of Hemophilia
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the European Medicines Agency (EMA) validated the Company's Marketing Authorization Application (MAA) for its investigational gene...
-
Dec 16, 2019Placebo-adjusted Increase in Growth Velocity of 1.6 cm/yr (p<0.0001) in Children Treated with Vosoritide Over One Year
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today reported positive final results from its randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy and safety of...
